Concepedia

Author

Tomohiro Enokida

National Cancer Center Hospital EastORCID

Also Known As

T. Enokida, Tomohiro Enokida

139

Publications

1.2K

Citations

17

H-Index

22

Concepts

All Affiliations

National Cancer Center Hospital EastChiba Cancer CenterEisai (United States)Eisai (Japan)Nagoya University
TE

About

Tomohiro Enokida is an author at National Cancer Center Hospital East specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

179

2

Health Sciences

1

1

15

3

Allergy

1

1

13

4

Allergy Medicine

1

1

13

5

Immunology

1

1

84

Tomohiro Enokida

×

23

Publications

910

Citations

15

H-Index

YearCitations

Lenvatinib for Anaplastic Thyroid Cancer

Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki,

Frontiers in Oncology

2017

188

A Phase II Study of the Safety and Efficacy of Lenvatinib in Patients with Advanced Thyroid Cancer

Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki,

Future Oncology

2019

137

A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma

Makoto Tahara, Susumu Okano, Tomohiro Enokida,

International Journal of Clinical Oncology

2021

103

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

Rafaela Kramer, Anne Zaremba, Alvaro Moreira,

European Journal of Cancer

2021

84

A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses

Cansu Cimen Bozkus, Ana-Belén Blázquez, Tomohiro Enokida,

STAR Protocols

2021

47

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study

Leonie Müller‐Jensen, Sarah Zierold, Judith M. Versluis,

European Journal of Cancer

2022

34

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck

Tomohiro Enokida, Takenori Ogawa, Akihiro Homma,

Cancer Medicine

2020

33

Microbiota-driven antitumour immunity mediated by dendritic cell migration

Yi-Tzu Lin, Shota Fukuoka, Shohei Koyama,

Nature

2025

28

Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.

Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki,

Journal of Clinical Oncology

2016

27

Phase Ii Study of Lenvatinib (Len), a Multi-Targeted Tyrosine Kinase Inhibitor, in Patients (Pts) with All Histologic Subtypes of Advanced Thyroid Cancer (Differentiated, Medullary and Anaplastic)

Shunji Takahashi, Makoto Tahara, Naomi Kiyota,

Annals of Oncology

2014

25

Page 1